Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Endocrine disorders – page 15

  • 504 clinical trials
  • 189 recruiting
  • 213 conditions
  • 25 countries

Conditions in this area

213 conditions with trials, the busiest first

Type 2 diabetes mellitus85Type 1 diabetes mellitus41Endocrine ophthalmopathy26Neuroblastoma26Obesity24Diabetes mellitus21Neuroendocrine tumour19Overweight18Gastroenteropancreatic neuroendocrine tumour disease16Diabetic neuropathy13Diabetic retinal oedema13Diabetic foot12Myotonic dystrophy12Adrenogenital syndrome11Neuroendocrine carcinoma11Thyroid cancer11Graves' disease10Hypoparathyroidism9Acromegaly8Adrenoleukodystrophy8Chronic kidney disease8Glucose tolerance impaired7Pancreatic neuroendocrine tumour7Adrenocortical carcinoma6+189

Clinical trials in Endocrine disorders

504 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

504 clinical trials

Diabetic retinopathy

Recruiting

Study on the Effectiveness of Somatostatin Eye Drops for Patients with Moderately Severe to Severe Non-Proliferative Diabetic Retinopathy

Investigational
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Somatostatin
  • Sponsor:Bcn Peptides S.A.

Type 1 diabetes mellitus

Recruiting

Study on Anti-T Lymphocyte Immunoglobulin for Children and Young Adults with Recent Type 1 Diabetes to Preserve Beta Cell Function

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years
  • Substances:Anti-T Lymphocyte Immunoglobulin For Human Use, Rabbit
  • Sponsor:Institute For Clinical And Experimental Medicine

Neuroendocrine tumour

Recruiting

Study on the Effect of Octreotide and Lanreotide in Peptide Receptor Radionuclide Therapy for Adults with Neuroendocrine Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Lanreotide
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Type 1 diabetes mellitus

Recruiting

Study on the Effect of Influenza Vaccine on Preserving Beta Cell Function in Early Type 1 Diabetes Patients

Registered drug
Countries:DenmarkDenmark
  • Participants:0–17 years
  • Sponsor:Region Midtjylland

Diabetic neuropathy

Recruiting

Study of Incobotulinumtoxin-A Injections for Diabetic Neuropathic Pain in the Lower Limbs

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Clostridium Botulinum Neurotoxin Type A (150Kd), Free Of Complexing Proteins
  • Sponsor:Rigshospitalet

Diabetic foot infection

Recruiting

Study on the Safety and Effectiveness of Contezolid Acefosamil, Contezolid, and Linezolid for Adults with Moderate or Severe Diabetic Foot Infections

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Aztreonam
  • Sponsor:Micurx Pharmaceuticals Inc.

Adrenocortical carcinoma

Recruiting

Study on Mitotane Alone or with Cisplatin and Etoposide for Patients with High-Risk Adrenocortical Carcinoma After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Amsterdam UMC Stichting

Neuroblastoma

Recruiting

Study of Lutetium (177Lu) Oxodotreotide for Children with Relapsed or Refractory High-Risk Neuroblastoma

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years
  • Substances:Edotreotide
  • Sponsor:Karolinska University Hospital

Glucose tolerance impaired

Recruiting

Study of Semaglutide for Treating Prediabetes in Women with Previous Gestational Diabetes

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years
  • Substances:Semaglutide
  • Sponsor:UZ Leuven

Neuroendocrine tumour+2

Recruiting

Study on Continuing Somatostatin Analogues with Sunitinib, Octreotide, and Lutetium (177Lu) Oxodotreotide for Patients with Neuroendocrine Tumors

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Antwerp University Hospital

Type 2 diabetes mellitus

Recruiting

Study on Sodium Phenylbutyrate for Improving Blood Sugar Control in Type 2 Diabetes Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Phenylbutyrate
  • Sponsor:Universiteit Maastricht

Neuroendocrine tumour+1

Recruiting

Study Comparing 177Lu-Edotreotide and Everolimus for Patients with Neuroendocrine Tumors in the Lung and Thymus

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Grupo Espanol De Tumores Neuroendocrinos

Substances studied in this area

The therapies tested most often in Endocrine disorders trials.

Semaglutide48 clinical trialsDapagliflozin21 clinical trialsEmpagliflozin14 clinical trialsMetformin Hydrochloride13 clinical trialsMetformin12 clinical trialsSodium Chloride12 clinical trialsCisplatin11 clinical trialsEtoposide11 clinical trialsLutetium (177LU) oxodotreotide11 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.